Stockreport

Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results

Paratek Pharmaceuticals, Inc.  (PRTK) 
Last paratek pharmaceuticals, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.paratekpharma.com
PDF --NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI -- -- SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne [Read more]